Back to top

Analyst Blog

Idenix Pharmaceuticals’ loss of 17 cents per share in the fourth quarter of 2012 was a penny below the year-ago loss and in-line with the Zacks Consensus Estimate.

The company’s fourth quarter 2012 revenues were $0.3 million up from ($0.7) million in the year-ago period, but below the Zacks Consensus Estimate of $1 million. Revenues in the year-earlier period suffered from a charge against revenues worth $3.4 million.

Full-year 2012 adjusted net loss came in at 21 cents per share, narrower than the year-ago loss of 57 cents and the Zacks Consensus Estimate of a loss of 25 cents per share.

Full-year revenues came in at $69.7 million, significantly above $6.9 million in 2011. This massive increase was due to the recognition of $36.1 million as deferred revenues in relation to the termination of a license agreement with ViiV Healthcare Company.

Full-year revenues were slightly below the Zacks Consensus Estimate of $70 million.

The Quarter in Detail

Research and development expense during the quarter increased 37.2% year over year to $17.5 million.

General and administrative expense increased 67.4% year over year to $7.3 million.

Pipeline Update

In Jan 2013, Idenix inked a collaboration agreement with Janssen Pharmaceuticals, Inc.− a Johnson & Johnson (JNJ - Analyst Report) company – for the development of all-oral direct acting antiviral (DAA) Hepatitis C Virus (HCV) therapies. The collaboration covers IDIX719, simeprevin (TMC435) and TMC647055. The drug-drug interaction study is expected to begin in the first quarter of 2013.

Idenix will also file an investigational new drug application (IND) for uridine-based nucleotide analog candidate in the first half of 2013.

Idenix, a biopharma company, currently carries a Zacks Rank #3 (Hold). Other biopharma stocks like Cytokinetics Incorporated (CYTK - Snapshot Report) and Array BioPharma Inc. (ARRY - Snapshot Report) currently look more favorable. Cytokinetics carries a Zacks Rank #1 (Strong Buy), whereas Array carries a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%